MedTrace Logo

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

NCT00584025 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-11-16

No results posted yet for this study

Summary

The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.

Conditions

Interventions

DRUG

levetiracetam

100 - 500mg IV q 15 min

DRUG

Placebo

Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa A Zesiewicz, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584025 on ClinicalTrials.gov